Conclusions and Recommendations Key messages for at-risk populations: The EVOKE trial failure does not invalidate GLP-1 agonists for preventionthe epidemiological signal remains strong, and these drugs may provide metabolic and cardiovascular benefits with potential cognitive co-benefits when used for approved indications SS-31s approval establishes precedent for mitochondrial-targeted therapeuticswatch this space for expanded indications Popular biohacker peptides (BPC-157, Dihexa, P21) have essentially no human cognitive evidence
Agladoglu SY, Cetnkaya S, Savas Erdeve S, Onder A, Kendrc HNP, Bas VN, Aycan Z
Each serving consists of 3000 mg of supplement
A thorough medical evaluation, including blood work to check IGF-1 levels and overall hormone status, is the safest first step before starting therapy
Discussion In this study, we have identified that the lipid transfer protein ATG2A is an S-palmitoylated protein that undergoes depalmitoylation in cells under starvation conditions
Nutr Metab (Lond) 19 , 60 (2022)
